Novelty Nobility Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Novelty Nobility Inc. - overview
Established
2017
Location
Seongnam, Gyeonggi-do, South Korea
Primary Industry
Biotechnology
About
Based in Seongnam, South Korea, and founded in 2017 by Sang Gyu Park (CEO), Novelty Nobility Inc. , is a biotech company that works on the development and discovery of therapeutic antibodies, antibody-drug conjugates (ADCs), and ADC linker technologies to cure cancer and other medical conditions. In May 2022, Novelty Nobility Inc. raised KRW 34.
1 billion in Series B funding from new investors Albatross Investment, KB Investment, KB Securities, NH Investment & Securities, Samho Green Investment, SL investment, and others. The company is working on four drugs: NN2101, a monoclonal retinal disease therapeutic drug, NN3201, an antibody drug conjugate anti-cancer drug, NN2802, a chronic urticaria treatment drug, and NN3206, an ADC cancer drug with a pan-RAS inhibitor concept. Furthermore, the company has a PREXISE-D monoclonal antibody (mAbs) design and discovery platform that conducts human and mouse experiments to develop multi-purpose antibodies. PREXISETM-L is another patented, proprietary linker platform technology of the company that allows for the site-specific conjugation of various payloads to an intact antibody.
Novelty Nobility Inc. intends to use the May 2022 funding for its retinal disease treatment's initial clinical trials and the preclinical development of its anticancer drug.
Current Investors
Shinhan Venture Investment, P&I Investment, QUAD Ventures
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy, Oncology/Cancer Treatment
Website
www.noveltynobility.com
Company Stage
Series C
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.